



## MEETING DATES - THE SECOND SATURDAY OF THE MONTH

June 11, July 9, and August 13, 2022

The Heartland MGA group's scheduled time and place to meet is 10:00 AM, the second Saturday of each month at Calvary Lighthouse Church, **2941 N. 80**<sup>th</sup> **Street, Omaha NE 68134.** Calvary is located just north of Maple **on** 80<sup>th</sup> Street.

Our meetings take place in the upstairs conference room. Parking is up front (third driveway on the right from the corner of 80<sup>th</sup> and Maple) and enter where the sign says Education Center.

Saturday, May 14, 2022, the Heartland Myasthenia Gravis Association Support Group met for their normally scheduled meeting. There were 10 in attendance.

The group welcomed Mark, a new visitor. As is the custom with someone new, each member introduced themselves and gave a brief history of their disease and any medications they're on.

## **Information shared:**

UCB is conducting Phase 3 trials for Zilucoplan, which blocks the complement system gMG and Rozanolxiizumab, which reduces the time antibodies remain in circulation. UCB is seeking approval for these two new treatments this year (2022)

Long-term Vyvgart eases gMG symptoms – is safe and well tolerated. Phase 3, three-year extension of ADAPT (NCT03669588) is evaluating the long-term safety, tolerability, and effectiveness of intravenous Vyvgart in adults with generalized MG,

The US Food and Drug Administration has approved Milla Pharmaceuticals' generic version of Mestinon (pyridostigmine bromide) for treating the symptoms of MG. The new generic, available as a syrup, is expected to launch soon in the U.S.

Ultomiris has been approved in the U.S. for adults with gMG. It has a long-acting C5 inhibitor.

Anti-thyroid antibodies tied to specific immune profile in MG showed a higher proportion of patients had ocular MG.

Treasurer, Kathy Cassidy reported \$790.94 in the treasury, and a check in the amount of \$3,000.00 from the John and Constance McClurg estate to be deposited.